You are here

Home » Content

Ürdün'ün Kuzey Bölgesindeki Kan Donörlerinde Toxoplasma gondii Antikorunun IgG, IgM Prevalansı

Prevalence of IgM And IgG Antibodies to Toxoplasma gondii in Blood Donors in the North Region of Jordan

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
A total of 1500 blood donors were examined for Toxoplasma gondii antibodies (IgG), and (IgM), by serological techniques. Eighty normal cross matched controls were subjected to the same examination. The aim of this study is to examine the sero prevalence rate of Toxoplasma gondii in northern region of Jordan population among blood donors. A retrospective study was carried out at Prince Rashid Bin Al-Hassan Military Hospital in the north region of Jordan over one year period in 1999. Fresh blood samples were randomly drawn from all donors. Serum was separated and stored at -20 C° until it was tested. Toxoplasma gondii antibodies were detected using the Enzyme Linked Immunosorbent Assay (ELISA ). A total of 1500 (1200 males, 300 females) blood donors were screened for toxoplasma gondii antibodies IgG and IgM. The prevalence of toxoplasma among the study population was 35.5% and the prevalence in males and females were 35.8% and 34.3% , respectively. The peak age range of toxoplasma gondii antibodies IgG donors among males 20 to 29 years; followed 30 to 39, 40 to 49, and< 20 years respectively. Among the female donors, the highest detection of Toxoplasma gondii antibodies IgG was between the ages of 20 to 29, followed by 30 to 39 years, < 20 years and by age from 40-49 years, respectively. The lowest seropositivity was in the age group > 50 years among males and females. So we concluded that seropositivity in our donors was significant, and previous studies carried out in Jordan and other countries indicated the high prevalence of Toxoplasma gondii infection. The results obtained in this study, expanded immunization programme must be introduced considering all age groups. Future studies are necessary to determine the prevalence of Toxoplasma gondii antibodies in more common populations by using sensitive screening methods.
Bookmark/Search this post with
Abstract (Original Language): 
Ürdün'ün Kuzey bölümünde yaşayan 1500 uygun kan donörü Toxoplasma gondii antikoru varlığı yönünden tarandı. Bu çalışmanın amacı, Ürdün populasyonundaki kan donörlerinde Toxoplasma gondii antikorunun (IgG, IgM) seroprevalansını değerlendirmektir. Bu amaçla 1999 yılında Prince Rashid Bin Al-Hassan Military Hospital'da retrospektif bir çalışma yapıldı ve veriler toplandı. Bütün donörlerden taze kan örnekleri alınarak, serumlar ayrıldı ve test yapılana kadar -20 °C'de saklandı. Toxoplasma gondii antikorları IgG, IgM ELISA testi (DiaSorin Entities, ETI -Toxok-G plus) kullanılarak, toplam 1500 kan donörü (1200 erkek, 300 kadın) Toxoplasma gondii IgG and IgM antikorları yönünden incelendi. Çalışma populasyonu içerisinde Toxoplasma gondii IgM antikorları saptanmadı. Toxoplasma gondii IgG olgularını n prevalansı %35.5 olarak belirlenirken erkek ve kadınların prevalansları ise sırası ile %35.8 ve %34.3 bulundu. Toxoplasma gondii pozitif donörlerin pik yaş aralığı 20-29 olarak belirlendi. Donörlerimizde seropozitiflik oranının belirgin olarak yüksek olduğu kararına varıldı. Bu nedenle, genişletilmiş immünizasyon programları oluşturularak, bütün yaş gruplarına uygulanması, Toxoplasma gondii markırlarının ölçümünde daha duyarlı tarama yöntemleri kullanılarak, daha geniş poplusyonlarda Toxoplasma gondii prevalansının saptanması gerektiği kanısına varılmıştır .
FULL TEXT (PDF): 
PDF icon arastirmax-urdunun-kuzey-bolgesindeki-kan-donorlerinde-toxoplasma-gondii-antikorunun-igg-igm-prevalansi.pdf
  • 3
143-146
  • Turkish

REFERENCES

References: 

1. National Center for Health Statistics. Plan and operation of the third National Health and Nutrition Examination Survey, 1988-94. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, CDC. 1994; (Monthly vital statistics report; series 1, no. 32).
2. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999;5:607-25.
3. Freij BJ, sever JL. Toxoplasmosis,paed in Rev 1991;12.227-36.
4. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic diseases with combination antiretroviral therapy. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31 to February 5, 1998. Abstract 184.
5. Schmunis G, Zicker F, Cruz JR Cuchi P. Safety of blood supply for infectious disease in Latin American Countries, 1994-1997.Am J Trop Med Hyg 2001;65:924-930.
6. Stagno.S. congenital toxoplasmosis.Am J Dis Child 1980;134:635-7.
7. 7.Tabor E-Infectious complicatios of blood transfusion.New York:Academic Pres,1982.23Barbara JAJ,editor-Microbiology in blood transfusion
8. Holliman RE. Toxoplasmosis, postgrad Doctor (Middle East) 1992; 14: 455-60.
9. Art.Yaneza;prasanna Kumari. Prevalence of toxoplasma antibodies in blood donors in Al-Hassa .Ann Saudi Med. 1994 ; 14(3):230-232.
10. Morsey TA,Michael SA. Toxoplasmosis in Jordan.J Egyptian Soc. Parasit.1980
;47:148-50.
11. Susan MH.The diagnosis of toxoplasmosis.Br Med J 1984;289:570-571.
12. Jackson MH, Hutchinson WM.A seroepidemiological survey of toxoplasmosis in
Scotland and England.AnnTrop Med Parasit 1987;81(4):359-65
13. Behbehani k,AL-Karmi T. Epidemiology of toxoplasmosis in Kuwait I. Detection of antibodies to T .gondii and percentage distribution among inhabitants. Trans Roy Soc
Trop Med Hyg1980,74:209-12.
14. Kilic, NB, Yight,S and Özcan, K. Toxoplasma gondii ıGg and IgM antibodies in blood donors.Acta Parasitological Turoica .1995; 19:39-47.
15. Griffin L. Williams KA.Trans R Soc Trop Med Hyg. Serological and parasitological survey of blood donors in Kenya for toxoplasmosis. 1983;77(6):763-6.
16. Al-Amri OM: Prevalence of antibodies to Toxoplasma gondii among blood donors in
Abha, Asir region, South Western Arabia. J Egypt Public Health Assoc 1994;69:77-88.

Thank you for copying data from http://www.arastirmax.com